Caliway Biopharmaceuticals L Receivables

Caliway Biopharmaceuticals L (6919.TW) currently reports a receivables of $420K as of March 2026. That compares with $420K in the prior-year period — down 0.2% year over year. Use the charts on this page to explore Caliway Biopharmaceuticals L's receivables history and peer comparisons.

Caliway Biopharmaceuticals L's receivables decreased from $420K to $420K — a 0.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Caliway Biopharmaceuticals L reported $420K in receivables as of March 2026. That compares with $420K in the prior-year period — down 0.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $420K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Caliway Biopharmaceuticals L, and consider following 6919.TW for alerts when major investors trade the stock.

Caliway Biopharmaceuticals L is classified in the Healthcare sector. On receivables, it currently shows $420K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6919.TW with unrelated industries.